Predictmedix AI Accelerates Corporate Expansion During Month-Long International Campaign

TORONTO, ON / ACCESSWIRE / October 27, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), has just returned from a fruitful month of international endeavors, during which the company achieved significant milestones in corporate development.

Throughout its overseas venture, Predictmedix AI has made remarkable strides, reinforcing its commitment to innovation and excellence. These advancements encompass various domains and include:

• Strategic Alliances: Predictmedix AI has initiated multiple partnerships designed to drive business development across diverse verticals, with a strong focus on the healthcare sector. These partnerships are poised to redefine how AI-driven solutions impact the industry and beyond.
• Government Collaborations: Building on its commitment to regulatory alignment and government initiatives, Predictmedix AI has established vital partnerships with key government organizations to promote innovation and compliance.
• Enhanced Healthcare Engagement: During its overseas tenure, Predictmedix AI continued to deepen its engagement within the healthcare sector, demonstrating its ongoing dedication to transforming patient care and diagnosis using state-of-the-art AI technologies.
• Diversified Opportunities: Predictmedix AI has explored new opportunities in non-healthcare verticals, further expanding its footprint and leveraging its AI expertise to contribute to various industries.
• Key Talent Acquisition: The company has recruited key individuals with exceptional skills and experience, strategically enhancing the team to accelerate business development efforts.
• Certifications for Healthcare: In response to client requirements for commercial orders, Predictmedix AI is actively pursuing Bureau of Indian Standards (BIS) and Central Drugs Standard Control Organization (CDSCO) certifications to ensure the quality and compliance of its healthcare solutions.

Dr. Rahul Kushwah, COO of Predictmedix AI, expressed his enthusiasm: "Our overseas campaign has provided a unique platform to reaffirm our unwavering commitment to innovation, regulatory alignment, and the relentless pursuit of excellence, including many confidential discussions and arrangements. As situations continue to evolve, we will make appropriate disclosures."

Predictmedix AI is also pleased to confirm the company has established a corporate address in the San Francisco, USA.

These corporate developments emphasize Predictmedix AI's mission to revolutionize AI applications across various verticals, establishing the company as a global leader in advanced AI technologies.

The Company has also entered into agreements with two consultants who have provided services to the Company related to the development of the Company's technologies. As consideration for the services, the Company will issue 1,000,000 common shares to each consultant, for a total issuance of 2,000,000 common shares.

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes
Communications International (905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

SOURCE: Predictmedix AI Inc.